Product Description
A recombinant protein-based inhibitor of numerous types of kallikrein-related peptidases (KLKs), with potential antineoplastic activity. Upon administration, KLK inhibitor MDPK67b targets and inhibits various KLKs, including KLK2, KLK4, KLK5 and KLK14. This inhibits KLK-mediated signaling and inhibits the proliferation of tumor cells in which these KLKs are overexpressed. Deregulation of KLKs is associated with some types of cancers. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/kallikrein-inhibitor-mdpk67b)
Mechanisms of Action: KLK Inhibitor
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Med Discovery
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05580107 |
MDPK67b-2002 | P1 |
Unknown status |
Prostate Cancer |
2024-06-30 |
50% |
2025-12-02 |
Primary Endpoints |
NCT04839120 |
MDPK67b-1001 | P1 |
Completed |
Prostate Cancer |
2017-06-07 |
2021-04-10 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|